2016
Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis
Ying L, Zhang F, Pan X, Chen K, Zhang N, Jin J, Wu J, Feng J, Yu H, Jin H, Su D. Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget 2016, 5: 86536-86546. PMID: 27852032, PMCID: PMC5349933, DOI: 10.18632/oncotarget.13294.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerComplement component 7NSCLC patientsPotential tumor suppressorOvarian cancerOvarian tissueMultivariate Cox regression analysisLow expressionZhejiang Cancer HospitalIndependent prognostic predictorCox regression analysisPrognosis of patientsAdvanced clinical stageCell lung cancerNormal ovarian tissuesExpression of C7Malignant ovarian tissuesTumor suppressorQuantitative polymerase chain reactionCancer HospitalClinical stagePrognostic predictorLung cancerPolymerase chain reactionPoor differentiation
2014
Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers
Xu F, Zhang H, Su Y, Kong J, Yu H, Qian B. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clinical And Translational Oncology 2014, 16: 980-985. PMID: 24805982, DOI: 10.1007/s12094-014-1183-9.Peer-Reviewed Original ResearchConceptsFemale lung adenocarcinomaLung adenocarcinomaLung tissueTianjin Medical University Cancer HospitalCorresponding normal lung tissuesCox proportional hazards modelMiR-183-3pProgression-free survivalLymph node metastasisLog-rank testNoncancerous lung tissuesPoor overall survivalLung cancer pathogenesisNormal lung tissuesLung cancer tissuesAdjacent noncancerous tissuesPotent prognostic markerPotential prognostic biomarkerProportional hazards modelT-testStudent's t-testBackgroundLung cancerOverall survivalNode metastasisClinicopathological characteristicsThe KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2013
Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma
Song M, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong L. Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma. PLOS ONE 2013, 8: e55761. PMID: 23437062, PMCID: PMC3577824, DOI: 10.1371/journal.pone.0055761.Peer-Reviewed Original ResearchConceptsDifferentially Methylated RegionsPromoter CpG islandsCpG islandsDNA methylationDifferential methylationMethylation changesGenome-wide methylation profilingDM locusGenome-wide levelDifferential methylation patternsAberrant DNA methylationPotential biological functionsSignificant differential methylationGene bodiesIllumina HumanMethylation450 BeadChipGenomic regionsIntergenic regionMethylated regionsMethylation patternsCellular developmentEpigenetic changesGene promoterGene listsMethylation profilingBiological functions
2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2011
Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women
Qian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research And Treatment 2011, 130: 217. PMID: 21562710, DOI: 10.1007/s10549-011-1552-9.Peer-Reviewed Original ResearchConceptsBreast cancer riskIGFBP-3 genotypesIGFBP-3 single nucleotide polymorphismsCancer riskChinese womenIGFBP-3Single nucleotide polymorphismsBreast cancerBreast tumorsTumor samplesLocal breast tissuesBreast cancer patientsIGF-I activityER-negative tumorsUnconditional logistic regressionCase-control studyFresh tumor samplesAge-matched controlsWilcoxon rank sum testRank sum testHigher peptide levelsIGFBP-3 geneIGF-I geneNegative tumorsCancer patients
2010
Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk
Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2010, 73: 138-146. PMID: 21195504, DOI: 10.1016/j.lungcan.2010.11.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedPolymorphism, GeneticRisk FactorsSmokingXeroderma Pigmentosum Group A ProteinXeroderma Pigmentosum Group D ProteinYoung AdultConceptsNon-small cell lung cancerLung cancer riskSquamous cell carcinomaLung cancerCancer riskCell carcinomaSingle nucleotide polymorphismsHigh riskGenetic polymorphismsNon-small cell lung cancer riskRisk of NSCLCCell lung cancer riskHigher lung cancer riskCell lung cancerVariant AA genotypeDominant risk factorNumerous epidemiological studiesLogistic regression modelsDNA repair pathway genesYoung smokersNSCLC casesSubgroup analysisRisk factorsHealthy controlsStratified analysisA KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancerABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer riskRacial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3
Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, Zheng W, Blot WJ. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine Related Cancer 2010, 17: 51-60. PMID: 19786462, PMCID: PMC2814999, DOI: 10.1677/erc-09-0023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedBlack or African AmericanBody Mass IndexBreast NeoplasmsCross-Sectional StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedPostmenopausePremenopauseProspective StudiesSoutheastern United StatesWhite PeopleYoung AdultConceptsBody mass indexAge 21 yearsBreast cancer riskIGF1 levelsRace/ethnicityIGFBP3 levelsMass indexWhite womenAA womenCancer riskRacial differencesPremenopausal breast cancer riskAfrican American race/ethnicityLower body mass indexEffect of obesityHigher IGF1 levelsCross-sectional analysisFree IGF1Serum IGF1IGF levelsBMI rangeAge 40Wide BMI rangeProtein 3Women
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patientsExercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials
Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psycho-Oncology 2009, 18: 343-352. PMID: 19242918, PMCID: PMC4221990, DOI: 10.1002/pon.1525.Peer-Reviewed Original ResearchConceptsPost-treatment survivorsBreast cancer survivorsQuality of lifeCancer survivorsPost-treatment breast cancer survivorsHospital-based tumor registryHome-based exercise programTrial of exerciseUsual care groupEffects of exerciseSocial functioningLower social functioningAdjuvant therapyUsual careExercise interventionTumor RegistryExercise programCare groupLife impairmentBreast cancerDepressive symptomsSurvivor subgroupsHigher baselineReduced qualityLife benefits
2008
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 2008, 101: 48-60. PMID: 19116382, PMCID: PMC2639294, DOI: 10.1093/jnci/djn415.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBiomarkers, TumorBlood GlucoseBody Mass IndexBreast NeoplasmsCase-Control StudiesEstradiolEstrogen Replacement TherapyFemaleHumansHyperinsulinismInsulinInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMiddle AgedMultivariate AnalysisObesityOdds RatioPostmenopauseProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsStatistics, NonparametricConceptsInsulin-like growth factorLevels of insulinBreast cancerInsulin levelsRisk factorsPostmenopausal womenGrowth factorMultiple breast cancer risk factorsMultivariable Cox proportional hazards modelsWomen's Health Initiative Observational StudyBreast cancer case subjectsBreast cancer risk factorsCox proportional hazards modelHormone therapy useIncident breast cancerIndependent risk factorPostmenopausal breast cancerCancer risk factorsCase-cohort studyProportional hazards modelTotal IGFNondiabetic womenBaseline characteristicsFree IGFProspective cohortAdipokine genes and prostate cancer risk
Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ. Adipokine genes and prostate cancer risk. International Journal Of Cancer 2008, 124: 869-876. PMID: 19035456, PMCID: PMC2879625, DOI: 10.1002/ijc.24043.Peer-Reviewed Original ResearchConceptsProstate cancer riskProstate cancerCancer riskOdds ratioIGF-1Prostate carcinogenesisADIPOQ geneBaseline blood drawCase-control studyAdipocyte-derived cytokineIGFBP-3Serum insulinLEP geneBlood drawFinnish menIntervention groupLarge cohortGG genotypeRelative oddsAdipokine genesAA genotypeCancerVariant allelesA alleleLogistic regressionHigh miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvementTGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stageA Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer
Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho G, Einstein M, Kaplan R, Burk R, Wylie-Rosett J, Pollak M, Anderson G, Howard B, Strickler H. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 921-929. PMID: 18398032, PMCID: PMC3090086, DOI: 10.1158/1055-9965.epi-07-2686.Peer-Reviewed Original ResearchMeSH KeywordsAgedBody Mass IndexCarcinoma, EndometrioidEndometrial NeoplasmsEstradiolFemaleHumansHypoglycemic AgentsInsulinInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Middle AgedMulticenter Studies as TopicObesityProportional Hazards ModelsProspective StudiesRisk FactorsConceptsInsulin-like growth factorEndometrial cancerEndometrioid adenocarcinomaRisk factorsFree IGFObese womenEstrogen levelsWomen's Health Initiative Observational StudyFree IGF-I levelsIGF-binding protein-3Growth factorBaseline serum specimensIncident endometrial cancerHormone therapy useIGF-I levelsMain histologic typesCase-cohort studyMajor risk factorHigh estrogen levelsTotal IGFPostmenopausal womenHormone therapyProspective cohortRandom subcohortTherapy useThe insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women
Strickler H, Howard A, Peters M, Fazzari M, Yu H, Augenbraun M, French A, Young M, Gange S, Anastos K, Kovacs A. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008, 22: 527-531. PMID: 18301066, PMCID: PMC3507535, DOI: 10.1097/qad.0b013e3282f22cdf.Peer-Reviewed Original ResearchConceptsHIV-positive subjectsHIV-positive womenHepatic stellate cellsIGFBP-3Liver diseaseAPRI levelsLiver fibrosisInsulin-like growth factor binding protein 3Insulin-like growth factor (IGF) axisGrowth factor binding protein 3CD4 T-cell countWomen's Interagency HIV StudyLarge multi-institutional cohortInsulin-like growth factor IBaseline serum specimensHigher IGFBP-3T-cell countsHigh-risk patientsMulti-institutional cohortGrowth factor axisHepatitis C virusLiver function test dataGrowth factor IBinding protein 3Extracellular matrix accumulationInsulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD. Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women. Cancer Research 2008, 68: 329-337. PMID: 18172327, PMCID: PMC4225702, DOI: 10.1158/0008-5472.can-07-2946.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorFree IGFColorectal cancerPostmenopausal womenEndogenous estradiolWaist circumferenceWomen's Health Initiative Observational StudyIncident colorectal cancer casesGrowth factorBaseline serum specimensColorectal cancer incidenceColorectal cancer casesEndogenous estradiol levelsColorectal Cancer StudyStrong mitogenic effectIndependent biological pathwaysTotal IGFObese patientsProspective cohortRandom subcohortNondiabetic subjectsEstradiol levelsRisk factorsCancer incidenceExtreme quartiles
2007
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
Smith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.Peer-Reviewed Original ResearchConceptsExcision repair cross-complementation group 1High ERCC1 expressionOvarian cancer patientsERCC1 expressionC genotypeDisease progressionGreater riskCancer patientsTreatment responseCodon 118Postoperative platinum-based chemotherapyEpithelial ovarian cancer patientsLow ERCC1 expressionSurvival of patientsPlatinum-based chemotherapyEpithelial ovarian cancerERCC1 mRNA expressionCombination of platinumERCC1 genotypePlatinum chemotherapyPoor prognosisOvarian cancerPaclitaxel treatmentGroup 1T genotype